Customer Service: 866-788-9007
Friendswood, TX – November 2, 2017 Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO will be presenting at Canaccord Genuity’s 2017 Medical Technologies & Diagnostics Forum on Thursday, November 9th, 2017 at 1:30 p.m. ET in New York City. About Castle Biosciences …
Catch the on-demand replay of “Personalizing Melanoma Management with Molecular Diagnostics” presented by Castle Biosciences’ Federico Monzon, MD. The presentation provides an overview of the use of molecular diagnostics in melanoma, from screening to monitoring therapy, and was part of a virtual event that focused on advancements in prevention, diagnosis and treatment of different cancer …
Friendswood, TX – September 5, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of the first prospective assessment of prognostic performance for the DecisionDx®-Melanoma test in a multi-center population of patients with cutaneous (skin) melanoma. The gene expression profile (GEP) test uses tumor biology …
Friendswood, TX–August 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that results of the DecisionDx®-Melanoma prognostic test’s performance in a cumulative cohort of 782 patients with cutaneous melanoma were presented during the 23rd International Pigment Cell Conference (IPCC 2017) held in Denver, CO from August …
Friendswood, TX – August 10, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of a study confirming the robust, reproducible performance characteristics of the DecisionDx®-UM test, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer. …
Friendswood, TX – July 18, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced three important milestones in improving access to DecisionDx®-UM, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer. Palmetto GBA, the administrator of the MolDX® …
Chicago, IL – June 5, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that three abstracts detailing results from studies of DecisionDx®-Melanoma were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6. Presentations included an …
Friendswood, TX – May 15, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma. The test uses tumor biology to provide an individual risk of recurrence in cutaneous …
ALEXANDRIA, Va. and SANTA CLARA, Calif. and FRIENDSWOOD, Texas.– May 9, 2017 – Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, and Silicon Valley Bank, the bank of the world’s most innovative companies and their investors, today announced the closing of a $20 million …
Friendswood, TX – May 1, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the prognostic accuracy of the DecisionDx®-Melanoma gene expression profile (GEP) test in a cohort of patients with head and neck melanoma. Results demonstrated that the DecisionDx-Melanoma test accurately …
